Bausch + Lomb Corporation (BLCO) Stock Score, Valuation & Financial Research
Bausch + Lomb Corporation is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for BLCO
Bausch + Lomb Corporation currently has a Wall Street Score of 24/100. The stored market price is $17.58. Its financial score is 45/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Bausch + Lomb Corporation does
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Ad
BLCO financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $17.58
- Market capitalization:
- $6.28B
- Revenue:
- $5.32B
- Net income:
- $-171.0M
- Free cash flow:
- $-66.0M
- Cash:
- $367.0M
- Total debt:
- $5.12B
- EPS:
- -0.48
- Financial score:
- 45/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-66.0M, showing cash burn in the current stored period.
- The balance sheet shows $367.0M of cash versus $5.12B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BLCO increased 0.1 points because overall fundamentals improved.
- The current research record carries a high debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 45/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BLCO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.